For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
28
views
303
references
 Top references
cited by
44
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      5,418
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p id="d6965775e746">Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy. </p>

          Related collections

          Most cited references303

          • Record: found
          • Abstract: found
          • Article: not found

          VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

          David Stojdl, Brian Lichty, Benjamin tenOever … (2003)
          Ideally, an oncolytic virus will replicate preferentially in malignant cells, have the ability to treat disseminated metastases, and ultimately be cleared by the patient. Here we present evidence that the attenuated vesicular stomatitis strains, AV1 and AV2, embody all of these traits. We uncover the mechanism by which these mutants are selectively attenuated in interferon-responsive cells while remaining highly lytic in 80% of human tumor cell lines tested. AV1 and AV2 were tested in a xenograft model of human ovarian cancer and in an immune competent mouse model of metastatic colon cancer. While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority of treated animals when delivered systemically.
          Article 0 comments Cited 256 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

            Igor Puzanov, Mohammed Milhem, David Minor … (2016)
            Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 checkpoint inhibitor) in patients with advanced melanoma.
            Article 0 comments Cited 243 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

              Zuqiang Liu, Roshni Ravindranathan, Pawel Kalinski … (2017)
              Both anti-PD1/PD-L1 therapy and oncolytic virotherapy have demonstrated promise, yet have exhibited efficacy in only a small fraction of cancer patients. Here we hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-L1 expression in cancer and immune cells, leading to more susceptible targets for anti-PD-L1 immunotherapy. Our results demonstrate in colon and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and induces PD-L1 expression on both cancer and immune cells in the tumour. The dual therapy reduces PD-L1+ cells and facilitates non-redundant tumour infiltration of effector CD8+, CD4+ T cells, with increased IFN-γ, ICOS, granzyme B and perforin expression. Furthermore, the treatment reduces the virus-induced PD-L1+ DC, MDSC, TAM and Treg, as well as co-inhibitory molecules-double-positive, severely exhausted PD-1+CD8+ T cells, leading to reduced tumour burden and improved survival. This combinatorial therapy may be applicable to a much wider population of cancer patients.
              Article 0 comments Cited 191 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: OncoImmunology
                Abbreviated Title: OncoImmunology
                Publisher: Informa UK Limited
                ISSN (Electronic): 2162-402X
                Publication date Created: September 07 2018
                Publication date Created: December 02 2018
                Publication date (Electronic): August 27 2018
                Publication date (Print): December 02 2018
                Volume: 7
                Issue: 12
                Page: e1503032
                Affiliations
                [1 ] Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
                [2 ] INSERM, Paris, France
                [3 ] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
                [4 ] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
                [5 ] Université Pierre et Marie Curie/Paris VI, Paris, France
                [6 ] McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada
                [7 ] Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada
                [8 ] Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
                [9 ] Department of Pathology, Dalhousie University, Halifax, NS, Canada
                [10 ] Department of Microbiology and Immunology, Dalhousie University, NS, Canada
                [11 ] Department of Biology, Dalhousie University, NS, Canada
                [12 ] Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada
                [13 ] Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
                [14 ] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
                [15 ] INSERM, Villejuif, France
                [16 ] Transgene S.A., Illkirch-Graffenstaden, France
                [17 ] Sotio a.c., Prague, Czech Republic
                [18 ] Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic
                [19 ] Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
                [20 ] Sandra and Edward Meyer Cancer Center, New York, NY, USA
                Article
                DOI: 10.1080/2162402X.2018.1503032
                PMC ID: 6279343
                PubMed ID: 30524901
                SO-VID: b2201030-0481-42de-8b31-acbba7d05d2c
                Copyright © © 2018
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content5,418

                See all similar

                Cited by44

                See all cited by

                Most referenced authors5,093

                See all reference authors